<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005096</url>
  </required_header>
  <id_info>
    <org_study_id>99-193</org_study_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>DFCI-99193</secondary_id>
    <secondary_id>NCI-G00-1757</secondary_id>
    <nct_id>NCT00005096</nct_id>
  </id_info>
  <brief_title>Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer</brief_title>
  <official_title>Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhone-Poulenc Rorer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have
      stage II or stage III prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the pathologic complete response rate to docetaxel in patients with
      high risk stage II or III prostate cancer. II. Determine the toxicity of this treatment in
      these patients. III. Correlate clinical measures of response (e.g., symptoms, physical exam,
      serum PSA, and endorectal MRI) with pathologic response to this treatment in these patients.

      OUTLINE: Patients receive docetaxel IV over 30 minutes weekly for 4 weeks. Treatment
      continues for 2-6 courses in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 19-45 patients will be accrued for this study over 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1999</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>2 Months, 6 Months</time_frame>
    <description>Wilcoxon Signed Rank Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with mild to moderate toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel given via iv at determined dose once a week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Potential candidate for radical prostatectomy

          -  Any of the following:

               -  Clinical stage T3 patients

               -  Serum PSA at least 20 ng/mL

               -  Gleason score 8-10

               -  Clinical T2 disease and either of the following:

                    -  MRI evidence of seminal vesicle involvement

                    -  Gleason 4+3 cancer with either 5 or 6 biopsies positive

          -  CALGB 0-1

          -  WBC greater than 3,000/mm3

          -  Hematocrit greater than 30%

          -  Platelet count greater than 100,000/mm3

          -  SGOT, total bilirubin within normal limits

          -  Signed Informed consent

        Exclusion Criteria:

          -  No prior hormones, radiation or chemotherapy for prostate cancer

          -  Evidence of serious active infection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary-Ellen Taplin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>March 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2004</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Mary-Ellen Taplin, MD</investigator_full_name>
    <investigator_title>Taplin, Mary-Ellen</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

